Citation: | GAO Ming, ZHANG Lian-dong, ZHANG Li, WANG Chang, LU Yan. Establishment of modified IgA nephropathy rat model and assessment of oxidative stress[J]. Journal of Clinical Nephrology, 2018, 18(4): 243-247. DOI: 10.3969/j.issn.1671-2390.2018.04.011 |
[1] |
Shu D, Xu F, Su Z, et al. Risk factors of progressive IgA nephropathy which progress to end stage renal disease within ten years:a case-control study[J]. BMC Nephrol, 2017, 18(1):11-16.
|
[2] |
乐伟波, 梁少珊, 邓康平, 等. 1126例中国汉族成人IgA肾病患者的长期预后及危险因素分析[J]. 肾脏病与透析肾移植杂志, 2011, 20(2):101-108.
|
[3] |
Kouchi M, Toyosawa K, Matsumoto I, et al. Hyaline glomerulopathy with tubulo-fibrillary deposits in young ddY mice[J]. Toxicol Pathol, 2011, 39(6):975-979.
|
[4] |
李冬. 大鼠肝衰竭前期模型建立及辅助性T淋巴细胞17/调节性T淋巴细胞失衡的研究[J]. 临床肝胆病杂志, 2016, 32(5):928-932.
|
[5] |
Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China:analysis based on 13,519 renal biopsies[J]. Kidney Int, 2004, 66(3):920-923.
|
[6] |
李慧琼, 刘帝, 刘烨歆, 等. IgA肾病发病机制研究纵览[J]. 临床肾脏病杂志, 2016, 16(12):708-712.
|
[7] |
Rifai A, Small PJ, Teague PO, et al. Experimental IgA nephropathy[J]. J Exp Med, 1979, 150(5):1161-1173.
|
[8] |
Tomino Y. Spontaneous animal model, ddY mouse, for studying the pathogenesis and treatment in patients with immunoglobulin A nephropathy[J]. Nephrology(Carlton), 2010, 15(1):1-6.
|
[9] |
Mestecky J, Novak J, Moldoveanu Z, et al. IgA nephropathy enigma[J]. Clin Immunol, 2016, 172:72-77.
|
[10] |
Xin Q, Li J, Dang J, et al. miR-155 Deficiency ameliorates autoimmune inflammation of systemic lupus erythematosus by targeting S1pr1 in faslpr/lpr mice[J]. J Immunol, 2015, 194(11):5437-5445.
|
[11] |
汤颖, 娄探奇, 成彩联, 等. 实验性IgA肾病模型的改进[J]. 中山大学学报(医学科学版), 2006, 27(2):184-187.
|
[12] |
Sheng X, Zuo X, Liu X, et al. Crosstalk between TLR4 and Notch1 signaling in the IgA nephropathy during inflammatory response[J]. Int Urol Nephrol, 2017, 36(3):521-523.
|
[13] |
Yeo SC, Cheung CK, Barratt J. New insights into the pathogenesis of IgA nephropathy[J]. Pediatr Nephrol, 2017, 42(3):463-470.
|
[14] |
Soares MF, Roberts IS. IgA nephropathy:an update[J]. Curr Opin Nephrol Hypertens, 2017, 26(3):165-171.
|
[15] |
Serafino A, Pierimarchi P, Pica F, et al. Thymosin alpha1 as a stimulatory agent of innate cell-mediated immune response[J]. Ann N Y Acad Sci, 2012, 1270:13-20.
|
[16] |
Liu F, Wang HM, Wang T, et al. The efficacy of thymosin alpha1 as immunomodulatory treatment for sepsis:a systematic review of randomized controlled trials[J]. BMC Infect Dis, 2016, 16(3):488-492
|
[17] |
李冬, 陆忠华, 甘建和. 肝衰竭前期大鼠模型的建立及辅助性T淋巴细胞17/调节性T淋巴细胞失衡的研究[J]. 临床肝胆病杂志, 2016, 32(5):928-932.
|
[18] |
Han C, Zhang L, Zhu X, et al. Plasma gelsolin levels are decreased and correlate with fibrosis in IgA nephropathy[J]. Exp Biol Med (Maywood), 2013, 238(11):1318-1327.
|
[19] |
Pei Y, Xu Y, Ruan J, et al. Plasma oxidative stress level of IgA nephropathy in children and the effect of early intervention with angiotensin-converting enzyme inhibitors[J]. J Renin Angiotensin Aldosterone Syst, 2016, 17(2):160-165.
|
[20] |
Zhu C, Mertens PR. IgA nephropathy and oxidative stress:news on clinically evaluated biomarkers hits the stage[J]. Int Urol Nephrol, 2012, 44(4):1277-1280.
|
[21] |
Tanaka S, Ninomiya T, Masutani K, et al. Prognostic impact of serum bilirubin level on long-term renal survival in IgA nephropathy[J]. Clin Exp Nephrol, 2015, 19(6):1062-1070.
|
[22] |
Wang Y, Tian J, Guo H, et al. Intermedin ameliorates IgA nephropathy by inhibition of oxidative stress and inflammation[J]. Clin Exp Med, 2016, 16(2):183-192.
|